HTT and juvenile Huntington disease: A global Gpr52 knockout, as well as GPR52 antagonist (E7) treatment has been reported to reduce Huntington’s disease-related symptoms and mutant huntingtin (mHTT) levels in mouse primary striatal neurons (28, 29).